These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 24911039

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation.
    Heilman RL, Nijim A, Desmarteau YM, Khamash H, Pando MJ, Smith ML, Chakkera HA, Huskey J, Valdez R, Reddy KS.
    Transplantation; 2014 Dec 27; 98(12):1310-5. PubMed ID: 24879384
    [Abstract] [Full Text] [Related]

  • 4. Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearance.
    Wu P, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI.
    Transplantation; 2013 Nov 27; 96(10):919-25. PubMed ID: 23912173
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation.
    Wiebe C, Nickerson P.
    Curr Opin Organ Transplant; 2013 Aug 27; 18(4):470-7. PubMed ID: 23695596
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prospective De Novo Donor-Specific Antibody Monitoring in Renal Transplant Patients.
    Fylaktou A, Sampani E, Kasimatis E, Nikolaidou V, Dimitriadis C, Anastasiou A, Papachristou M, Chatzika G, Papagianni A.
    Transplant Proc; 2021 Nov 27; 53(9):2765-2768. PubMed ID: 34598809
    [Abstract] [Full Text] [Related]

  • 11. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.
    Everly MJ, Briley KP, Haisch CE, Dieplinger G, Bolin P, Kendrick SA, Morgan C, Maldonado AQ, Rebellato LM.
    Transpl Int; 2017 Jun 27; 30(6):566-578. PubMed ID: 28211192
    [Abstract] [Full Text] [Related]

  • 12. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT, Gandhi J, Bray RA, Gebel HM, Morris A, McCue A, Yin M, Laskar SR, Book W, Jokhadar M, Smith A, Nguyen D, Vega JD, Gupta D.
    Clin Transplant; 2017 Apr 27; 31(4):. PubMed ID: 28181305
    [Abstract] [Full Text] [Related]

  • 13. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
    Bertrand D, Gatault P, Jauréguy M, Garrouste C, Sayegh J, Bouvier N, Caillard S, Lanfranco L, Galinier A, Laurent C, Etienne I, Farce F, François A, Guerrot D.
    Transplantation; 2020 Aug 27; 104(8):1726-1737. PubMed ID: 32732853
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
    Marfo K, Ajaimy M, Colovai A, Kayler L, Greenstein S, Lubetzky M, Gupta A, Kamal L, de Boccardo G, Masiakos P, Kinkhabwala M, Akalin E.
    Transplantation; 2014 Nov 27; 98(10):1082-8. PubMed ID: 24873780
    [Abstract] [Full Text] [Related]

  • 17. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
    Sharma A, Taverniti A, Graf N, Teixeira-Pinto A, Lewis JR, Lim WH, Alexander SI, Durkan A, Craig JC, Wong G.
    Pediatr Nephrol; 2020 Jun 27; 35(6):1061-1068. PubMed ID: 32065279
    [Abstract] [Full Text] [Related]

  • 18. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
    Pelletier RP, Rajab AA, Diez A, DiPaola NR, Bumgardner GL, Elkhammas EA, Henry ML.
    Clin Transplant; 2015 Dec 27; 29(12):1119-27. PubMed ID: 26382932
    [Abstract] [Full Text] [Related]

  • 19. Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d⁺ Antibody-Mediated Rejection in Kidney Transplant Recipients.
    Tatapudi VS, Kopchaliiska D, da Gente GJ, Buenaventura OF, Singh M, Laszik Z, Adey DB, Rajalingam R.
    Ann Transplant; 2021 Dec 01; 26():e934175. PubMed ID: 34848674
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.